Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms - A Multicenter, Randomized Study.

IF 1.8 3区 医学 Q3 UROLOGY & NEPHROLOGY
International Neurourology Journal Pub Date : 2023-09-01 Epub Date: 2023-09-30 DOI:10.5213/inj.2346148.074
Chih-Chieh Lin, Hann-Chorng Kuo, Jian-Ri Li, Yao-Chi Chuang
{"title":"Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms - A Multicenter, Randomized Study.","authors":"Chih-Chieh Lin,&nbsp;Hann-Chorng Kuo,&nbsp;Jian-Ri Li,&nbsp;Yao-Chi Chuang","doi":"10.5213/inj.2346148.074","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus cavernosum relaxation.</p><p><strong>Methods: </strong>In this 4-site, randomized controlled trial, 150 sexually active men with OAB were enrolled between June 2020 and May 2022. Participants were randomly allocated (1:2) into 2 treatment groups: (1) behavioral therapy alone (n = 50) and (2) a combination of mirabegron 50 mg daily and behavioral therapy (n = 100). The evaluation was based on the overactive bladder symptoms score (OABSS), the International Index of Erectile Function, the ejaculatory domain short form, the International Prostate Symptom Score, patient perception of bladder condition, quality of life, and urodynamic parameters. The therapeutic outcomes were assessed at baseline, 4 weeks, and 12 weeks.</p><p><strong>Results: </strong>There were 65 patients (65%) in the combination subgroup and 36 patients in the behavioral therapy who completed all 12 weeks of treatment. Both groups had a statistically significant improvement in OABSS after 12 weeks of treatment. The combination therapy group achieved a statistically significant improvement in all 4 subscores of OABSS, however, the urinary frequency (P = 0.120) and urinary incontinence (P = 0.234) subscores in the behavioral therapy only group did not show a significant change. Additionally, the combination group had a significant improvement in functional bladder capacity, which was not seen in the behavioral therapy group. However, both groups did not have a significant change in erectile or ejaculatory function.</p><p><strong>Conclusion: </strong>Behavioral therapy combined with mirabegron had more significant impact on the improvement of OAB than behavior therapy alone. However, both groups did not have significant changes in erectile or ejaculatory function.</p>","PeriodicalId":14466,"journal":{"name":"International Neurourology Journal","volume":"27 3","pages":"182-191"},"PeriodicalIF":1.8000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1d/82/inj-2346148-074.PMC10556431.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Neurourology Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5213/inj.2346148.074","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/30 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Purpose: We evaluated the therapeutic effects on overactive bladder (OAB) symptoms and sexual function of behavioral therapy with or without mirabegron in sexually active male patients with OAB. Mirabegron, a selective β3 adrenoceptor agonist for the treatment of OAB, has been shown to induce corpus cavernosum relaxation.

Methods: In this 4-site, randomized controlled trial, 150 sexually active men with OAB were enrolled between June 2020 and May 2022. Participants were randomly allocated (1:2) into 2 treatment groups: (1) behavioral therapy alone (n = 50) and (2) a combination of mirabegron 50 mg daily and behavioral therapy (n = 100). The evaluation was based on the overactive bladder symptoms score (OABSS), the International Index of Erectile Function, the ejaculatory domain short form, the International Prostate Symptom Score, patient perception of bladder condition, quality of life, and urodynamic parameters. The therapeutic outcomes were assessed at baseline, 4 weeks, and 12 weeks.

Results: There were 65 patients (65%) in the combination subgroup and 36 patients in the behavioral therapy who completed all 12 weeks of treatment. Both groups had a statistically significant improvement in OABSS after 12 weeks of treatment. The combination therapy group achieved a statistically significant improvement in all 4 subscores of OABSS, however, the urinary frequency (P = 0.120) and urinary incontinence (P = 0.234) subscores in the behavioral therapy only group did not show a significant change. Additionally, the combination group had a significant improvement in functional bladder capacity, which was not seen in the behavioral therapy group. However, both groups did not have a significant change in erectile or ejaculatory function.

Conclusion: Behavioral therapy combined with mirabegron had more significant impact on the improvement of OAB than behavior therapy alone. However, both groups did not have significant changes in erectile or ejaculatory function.

Abstract Image

Abstract Image

行为治疗和行为治疗加用Mirabegron 50 mg治疗性活跃男性肉毒杆菌素膀胱过度活跃症状的比较研究——一项多中心随机研究。
目的:我们评估了在性活跃的男性OAB患者中,使用或不使用米拉贝隆的行为疗法对膀胱过度活动(OAB)症状和性功能的治疗效果。Mirabegron是一种用于治疗OAB的选择性β3肾上腺素受体激动剂,已被证明可诱导海绵体松弛。方法:在这项4站点随机对照试验中,150名性活跃的OAB男性在2020年6月至2022年5月期间入选。参与者被随机(1:2)分为两个治疗组:(1)单独的行为治疗(n=50)和(2)每天50 mg的米拉贝隆和行为治疗的组合(n=100)。评估基于膀胱过度活动症状评分(OABSS)、国际勃起功能指数、射精域缩写、国际前列腺症状评分、患者对膀胱状况的感知、生活质量和尿动力学参数。在基线、4周和12周评估治疗结果。结果:联合治疗组有65名患者(65%),行为治疗组有36名患者完成了全部12周的治疗。治疗12周后,两组的OABSS均有统计学意义的改善。联合治疗组在OABSS的所有4个分量表中都获得了统计学上显著的改善,然而,仅行为治疗组的尿频(P=0.120)和尿失禁(P=0.234)分量表没有显示出显著的变化。此外,联合治疗组的膀胱功能有显著改善,这在行为治疗组中没有发现。然而,两组患者的勃起或射精功能均未发生显著变化。结论:与单纯行为疗法相比,行为疗法联合米拉贝隆对OAB的改善作用更为显著。然而,两组患者的勃起或射精功能均未发生显著变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Neurourology Journal
International Neurourology Journal UROLOGY & NEPHROLOGY-
CiteScore
4.40
自引率
21.70%
发文量
41
审稿时长
4 weeks
期刊介绍: The International Neurourology Journal (Int Neurourol J, INJ) is a quarterly international journal that publishes high-quality research papers that provide the most significant and promising achievements in the fields of clinical neurourology and fundamental science. Specifically, fundamental science includes the most influential research papers from all fields of science and technology, revolutionizing what physicians and researchers practicing the art of neurourology worldwide know. Thus, we welcome valuable basic research articles to introduce cutting-edge translational research of fundamental sciences to clinical neurourology. In the editorials, urologists will present their perspectives on these articles. The original mission statement of the INJ was published on October 12, 1997. INJ provides authors a fast review of their work and makes a decision in an average of three to four weeks of receiving submissions. If accepted, articles are posted online in fully citable form. Supplementary issues will be published interim to quarterlies, as necessary, to fully allow berth to accept and publish relevant articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信